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Chemotactic Factor Inactivator in Normal Human Serum
JEFFREY L. BERENBERG and PETER A. WARD
From the Walter Reed Army Institute of Research, Washington, D. C. 20012
and the Department of Pathology, The University of Connecticut Health
Center, Farmington, Connecticut 06032

A B S T R A C T Normal human serum contains an inactivator of chemotactic factors for neutrophilic leukocytes.
The chemotactic factor inactivator (CF-I) remains soluble when serum is fractionated with ammonium sulfate
(at 45% saturation), directly and irreversibly inactivates chemotactic factors, and it has a broad spectrum
of activity as indicated by its inactivation of the chemotactic fragments of human C3 and C5 (third and fifth
components of complement), C567, and the bacterial
chemotactic factor derived from Escherichia coli. CF-I
appears as a biphasic activity according to preparative
techniques of sucrose density ultracentrifugation, electrophoresis, and gel filtration. Studies on the interaction
of CF-I with the radiotagged C5 chemotactic fragment
fail to reveal evidence for irreversible binding as the
basis for inactivation. CF-I varies from the anaphylatoxin inactivator in several physical-chemical respects,
but evidence does not permit a conclusive statement
about the relationship of the two inactivators. CF-I may
function as a regulator of inflammatory responses.

INTRODUCTION
The acute inflammatory response is mediated by a variety of factors which either increase vascular permeability or lead to the leukotactic accumulation of neutrophils. The mediators themselves are chemically diverse,
ranging from peptides (the kinins, anaphylatoxins,
and chemotactic factors) to substances of very low
(< 1,000) molecular weight (e.g. the vasoactive amines).
As typified by the complement-derived leukotactic factors (from the third, C3, and fifth, C5 components of
complement), a diversity exists not only in structure
but also in the generation of these inflammatory mediators. For example, C3 and C5 can be cleaved productive
of anaphylatoxin and leukotactic fragments not only by
enzymes intrinsic to the complement system, but also by
Received for publication 22 August 1972 and in revised
form 26 October 1972.

1200

enzymes extrinsic to complement, such as plasmin, trypsin, thrombin, and tissue derived neutral proteases (reviewed in 1).
In spite of the remarkable diversity of mediators, the
inflammatory response is kept in balance by naturally
occurring inhibitors. For instance, the kinins and the
anaphylatoxins are destroyed almost immediately upon
generation in serum. This phenomenon of inactivation
has been related to the existence in serum of a carboxypeptidase B enzyme that inactivates the kinins and the
anaphylatoxins by removal of the C-terminal arginine
residue in the peptides (2). In this report we describe
the presence in normal human serum of a chemotactic
factor inactivator. It seems likely that the function of
this inactivator is to provide regulatory control over
the leukotactic mediators generated in serum.

METHODS
Chemotactic assays. Chemotaxis was performed by the
micropore filter technique in modified Boyden chambers.
This technique has been previously described in detail (3, 4).
Filters of 0.65 gm pore size (Millipore Corp., Bedford,
Mass.) were used and chemotactic activity quantitated by
counting the numbers of cells which had migrated through
channels of filters in five high power fields under light
microscopy. Rabbit neutrophils from glycogen-induced peritoneal exudates were the indicator cells. The upper compartment of each chemotaxis chamber contained a total of
2.5 X 106 neutrophils in 0.1% bovine serum albumin (BSA).
The bottom compartment of each chamber contained the
fluids to be tested for chemotactic activity. Hank's medium
(Microbiological Associates, Inc., Bethesda, Md.) was used
for dilution of both cells and fluids. For convenience, rabbit
neutrophils were the usual indicator cell. However, the
results tested in Tables I, II, and IV were reproduced using
human neutrophils as the indicator cells. Only the data obtained with rabbit neutrophils are listed in this report.
In all cases where studies of the chemotactic factor were
carried out, the chemotactic factor inactivator was mixed
with 50 dAI Escherichia coli bacterial factor (see below) or
other chemotactic factors, as indicated. After incubation at
room temperature for 30 min, this mixture was adjusted
to 1.0 ml with Hank's medium and the chemotactic assay
carried out. Per cent inhibition was determined by calculat-
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ing the ratio of chemotactic activity in the presence of
the inactivator and in its absence, times 100 and subtracting
from 100.
P'reparation of clhemotactic bacteria: bacterial factor was
ohtained from culture supernatants (in 1-ank's medium) of
E. coli sterilized by filtration through a Micropore filter
(5). 50 ul of this factor were used as the standard source
of chemotactic factor unless otherwise indicated.
Preparation of complement cilemnotactic factors. Human
C3 and C5 were purified according to the method of Nilsson
and Mfiller-Eberhard (6), which included a combination of
isoelectric precipitation, ion exchange chromatography, hydroxyl apatite chromatography, and preparative electrophoresis. Chemotactic fragments of C3 were produced by
treatment with trypsin (Mann Research Labs., Inc., New
York) according to the procedure of Bokisch and MullerEberhard (2). Chemotactic fragments of C5 were obtained
in a similar manner (7). Except where indicated, these
solutions were not fractionated further. In one experiment
1 mg unlabeled C5, mixed with 0.1 mg radiotagged C5 (by
the iodine monochloride method, 12), was treated with 100
,ug trypsin (in a reaction volume of 0.5 ml) at 320C X 20
min. The reaction was stopped by addition of 200 /Ag soybean trypsin inhibitor (Mann Research Labs., Inc.) contained in a volume of 50 A1 in phosphate-buffered saline.
The trypsinized (and chemotactically active) C5 material
was then fractionated by gel filtration, as described below.
A zone of radioactivity near the void volume of the eluted
column was found, as well as one near the cytochrome
marker. The radioactivity in the latter zone was pooled and
used as the source of chemotactically active CS fragment
(7). Human C567, activated by trypsin treatment of C567
(8), was kindly provided by Doctors C. Arroyave and H. J.

Mfiller-Eberhard.
Preparative electrophorcsis. Human serum was dialyzed
for 12 h against barbital buffer, pH 8.6, ionic strength 0.05.
Pevikon block electrophoresis was then carried out in the
same buffer for 18 h (9). The resulting fractions were
dialyzed for 12 h against phosphate buffer (pH 7.3, ionic
TABLE I
Presence of Chemotactic Factor Inactivator in Serum Fractions

Source of inactivator*

J. D., whole serum
J. D., supernate
J. D., precipitate
K. J., supernate
K. J., precipitate
NonelI

Volume of
inactivator
used+

100
150
300
300
300

Chemotactic§

Inhibition

activity

210
15
200
20
195
230

9
97
9
91
10

50 1.l chemotactic factors from E. coli used. Initials refer to
serum donors. Fractions of serum obtained by ammonium
sulfate at 45(%c saturation were employed. See text.
t None of these preparations were chemotactically active by
themselves.
§ Number of migrated cells in five high power fields, as in
reference 3.
1 Background chemotactic activity (in absence of bacterial
chemotactic factor) count of 20.
*

TABLE

1I1

Direct Effect of Inactimator on Bacterial Chenmotactic Factor
Inactivator* added to
cells

(upper)

Al
10
20

cliemotactic
factor

-

value

Inhibition
o/0

-

50O
-

Cheniotactic

10)
20
50
-

165
180
190
25
20
20
positive control: 190
negative controlt: 30

16
0
0
100
100
100

* Soluble ammonium sulfate fraction (45%) of normal
human serum, dialized and concentrated to 3 times the
original volume of serum. The inactivator was incubated for
30 min at room temperature with either cells or bacterial
chemotactic factor before the chemotactic assay.
T Hank's medium.
strength 0.05) before being tested for their ability to inhibit chemotactic activity.
Salt fractiowntion. Normal human serum was allowed
to clot for 2 h and then p)recil)itate(l with ammonium sulfate
at 40 or 45% saturation at 50C. (No differences in yield
or behavior of the chemotactic factor inactivator were noted
under these two conditions of fractionation.) The supernate was then dialyzed for 48 h against phosphate-buffered
saline. Unless otherwise indicated, the dialyzed fractions
wcre concentrated with PM-10 membrane (Amicon Corp.,
Lexington, Mass.) to one-third the original volume of serum
before assaying for chemotactic inactivator activity.

Ultraeentrifugation and gel chromatography . Ultracentrifugal characteristics of various preparations were determined by fractionation in a sucrose density gradient (7.535%c sucrose in phosphate buffer, pH 7.3, ionic strength
0.05) with centrifugation at 55,000 rpm for 16 h at 4VC
in an International Hematocrit Centrifuge (International
Equipment Co., Boston, Mass.), B-60 using a swinging
bucket rotor (4). Gel chromatography was carried out with
Biogel P200 (Bio-Rad Laboratories, Richmond, Calif.) in
phosphate-buffered saline. The proteins human IgG, BSA,
and cytochrome c were used as markers in ultracentrifugal
and gel filtration techniques. The same markers have been
used previously (7).
RESULTS
Salt fractionation of chemtotactic factor inactivator.
When the bacterial factor from E. coli was treated with
100 al whole human serum no significant loss of chemotactic activity was noted (Table I). At the present time
at least 20 different whole normal human sera have been
tested and found to be lacking in ability to inhibit chemotactic activity. However, when the various ammonium
sulfate fractions from each of two sera were studied, it
was found that the soluble fraction of serum was sig-
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IgG BSA cytochrome

described in Table I, increasing amounts ot this material
added either to the leukocyte suspension or to the
bacterial chemotactic factor and then incubated for 20
min at room temlperature. Table II shows the results of
these experiments. When 10-50 /l inactivator was incubated with cells, 11o effect on chemnotactic activity
was noted. However, as little as 10 /l inhibitor added
directly to the bacterial factor completely eliminated
chemotactic activity. These results indicate that the
inhibitor present in the 45% ammonium sulfate soluble
fraction of human serum acts directly on the chemotactic
factor (rather than on the cells) to render it inactive.
When large amounts of inhibitor (> 50 /Al) were added to
the cell suspension, decreased chemotactic responses
were found, presumably due to an effect of the inhibitor
on the diffusing chemotactic factor.
Irreversible nature of the chemotactic factor inhibitor.
The inactivator (described above) was mixed with the
bacterial chemotactic factor under a variety of conditions. Bacterial chemotactic factor boiled for 15 min
showed no loss of activity (Table III). When the inactivator was added to the boiled bacterial chemotactic
factor, 63% loss of chemotactic activity resulted. The
prior boiling of the inactivator abolished most of the
inhibitory effect on chemotactic activity (Table III, 15%
loss), whereas boiling the mixture of inactivator and
chemotactic factor (after they had been incubated together) failed to restore the chemotactic activity (59%
loss). These results indicate that the chemotactic factor
inactivator acts in an irreversible manner on the bacterial chemotactic factor to render it inactive.
Broad spectrum of activity of inactivator on chemotactic factors. The previous experiments indicated that
the inactivator present in the soluble (and concentrated)
fraction of ammonium sulfate-treated human serum could
inactivate the bacterial chemotactic factor. The data in
Table IV demonstrate that the inactivator has a rather
were
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FIGURE 1 Patterns of chemotactic factor inactivator in
ammonium sulfate-soluble fractions from two normal human
sera, separated by density gradient ultracentrifugation. 50
,al bacterial chemotactic factor was incubated with each
fraction from the gradients at 25'C X i h, the mixture then
assayed for residual chemotactic activity. In each of the
preparations two zones of inhibitor are present.

nificantly inhibitory for the chemotactic factors when
appropriate volumes were used. No inhibitory activity
could be demonstrated in the redissolved precipitate,
indicating that the chemotactic factor inactivator is
associated with a fraction of serum other than the
Ig-rich fraction.
Direct action of inactivator on the chemotactic factor.
These experiments were designed to determine if the inactivator was directly affecting the chemotactic factors
or the indicator leukocytes. Using the ammonium sulfate soluble (concentrated) fraction from normal serum
TABLE II I
Irreversible Effect of Chemotactic Factor Inactivator
Material tested*

Blank
Bacterial factor
Bacterial factor boiled (15 min)
Bacterial factor + inactivator,
370C X 20 min, then boiled (15 min)
Bacterial factor + boiled (15 min)
inactivator, 370C X 20 min
Boiled (15 min) bacterial factor + inactivator, 370C X 20 min

Chemotactic
activity: Inhibition§

25
240
270

4

O

0

100

59

205

15

90

63

* Source of bacterial chemotactic factor was 50 IAI culture
supernate (sterilized by filtration) from E. coli. Chemotactic
factor inactivator was the concentrated and dialized soluble
fraction after precipitation of normal human serum with
ammonium sulfate at 457% saturation. A volume of 20 ul
was used.
t Counts of migrated cells in five high power fields.
§ Per cent.
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FIGURE 2 Elution from Biogel 200 of the soluble fraction
of human serum obtained with ammonium sulfate at 45%o
saturation. From each sample 100 gI volumes were incubated
with 50 ,tl bacterial chemotactic factor at 250C X a h, then
assayed for residual chemotactic activity. Two zones of
inhibitor are present. Protein was measured in the Folin
reaction.

broad range of activity on chemotactic factors. The
chemotactic activity of human serum, treated with zymosan (4), the complement-derived chemotactic factor
C567 and the chemotactic fragments of C3 and CS, and
the E. coli bacterial factor were all inhibited. Thus, the
cheemotactic inactivator obtained from human serum is
able to inactivate both complement-derived and comnplement-independent chemotactic factors. Reasons for the
different degrees of inactivation (59-96%,, Table IV) of
various chemotactic factors are not known at the present
time.
Ultracetarifuigal analysis of chesnotactic factor blactivator. Sucrose density gradient ultracentrifugation was
performed to determine physical-chemical characteristics
of the chemotactic factor inactivator. Two inhibitor-rich
preparations, threefold concentrates of ammonium sulfate-soluble fractions, as described above, from two
different human sera were studied. The results are
shown in Fig. 1. For these experiments 50 ,/l bacterial
chemotactic factor was added to each of the 16 fractions
from the density gradients incubated for 2 h at room
temperature, then diluted to 1 ml in Hank's medium and
tested for residual chemotactic activity. Both frames in
Fig. 1 indicate that inactivator activity is biphasic, appearing at or below the lgG marker, and near the albumin (BSA) marker. These results suggest that the
chemotactic factor inactivator in serum is heterogenous
and can be resolved into at least two different fractions.
Isolation of chemotactic factor iniactivator by mtolecular sicvinig. The inactivator-rich fraction of serum produced by ammonium sulfate treatment was chromatographed in Biogel-200 (Bio-Rad Laboratories) at pH
7.3 (Fig. 2). Two zones of inhibitor activity were
demonstrated: the first eluted between the IgG and
BSA markers, and the second near the cy}tochrome c
marker. As with the ultracentrifugal fractionation, these
data indicate a heterogeneity in the characteristics of
the chemotactic factor inactivator. In experiments not
listed here rechromatography of each of the two zones
of chemotactic factor inactivator has resulted in the
same chromatographic position of each inactivator as
in the original separation. This finding together with
those to be presented below suggests that the heterogeneity of the inactivator is due to two separate and
distinct substances.
Electrophoretic separation of the inactivator. 8 ml
normal human serum not previously fractionated was
electrophoresed in a Pevikon block at pH 8.6 and the
fractions (100 nml each) tested for ability to inhibit the
bacterial chemotactic factor was found to be present in
two zones corresponding to a- and P-globulin positions.
(Fig. 3). To what extent these two zones of inactivator
relate to the two zones found by ultracentrifugation and
gel filtration (Figs. 1 and 2) is not known.

INHIBITOR OF CHEMOTACTIC
FACTOR

-

80- (BACTERIAL)
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12

16

FIGURE 3 Electrophoretic separation of normal human
serum in Pevikon, pH 8.6, barbital buffer, ionic strength
0.05. Detection of inactivator was carried out, as described
in Fig. 2. Two zones of inhibitor are present, one in the
a-position, the other in the a-position towards the anode

(to right).
Aiechamisins of action/ of clheinotactic factor inactivator. None of the preceding experiments defined the
mechanism by which the inactivator interacts with
chemiotactic factors to render them inactive. To study
this question. the trypsin produced (and radio-labeled)
CD fragment was isolated and then incubated with the
inactivator. The source of the inactivator was the material eluting near the IgG marker front a Biogel column
(Fig. 2). This inactivator was concentrated to a volume
of one-third the original serum volume. 10 Ol inacti-ator
was incubated with 50 /4 C5 fragment (equivalent to
approximately 5 tug original CS) at room temperature
for 20 min, and then ultracentrifuged. The results are
seen in Fig. 4. Neither the amounts of radioactivity in
the gradient nor the position of the radioactivity seemed
TABLE IX
Inactivation oJ Several Cheniotactic Factors by Inoctiacltart
Chemotactic activity
Factor tested

Activated serum*
C567 (5 jg)
C3 fragment:
C5 fragment$
Bacterial factor
(50,l, from E. coli)

Inhibitor
absent

Inhibitor
iresent

200

5
30
35

Inhibition

145
280

10(0

96
89
59
65

250

90

64

280

* One-tenth human serum incubated with 1 mg zymosan (4).
In all experiments 20 ,ul inhibitor was used.
t 50 mg C3 or C5 chemotactically activated with trypsinl.
(See text).
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FIGURE 4 Sucrose density gradient analysis by ultracentrifugation of radio-tagged and chemotacticaIly active C5
fragment before (solid line) and after (dotteed line) treatment with inhibitor isolated in Fig. 2 (the in
was the one that eluted near the IgG marlker). Thoe inactivator does not cause a shift in the main Ipeak of radioactivity of the C5 fragment.

altered as a result of inactivation (Fig. 4,
when compared with the pattern for t brokent lie)d
chemotactic fragment (Fig. 4, solid line). Chemotactic
tests of the various fractions showed the
V)f
high levels of activity in fractions 12-14 p(TsblnceV,
whereas chemotactic activity in the same
with
ragment with
lost as a result of pretreatment of the C5 f :ragment
the inactivator (Table V). It should be po ted
with tht
in the preparation of C5 fragment trea
inactivator a small zone of radioactivity wEas seen in the
ultracentrifugal position of the inactivator (Fig. 4, fractions 8 and 9). The significance of the sm all amount of
radioactivity ('- 4% of total radioactivitty in the C5
fragment preparation) is unknown. Whi]le we cannot
rule out a highly reversible interaction, thLese data suggest that however the inactivator alters the C5 fragment
it is probably not due to substantial, irreve rsible binding
to the chemotactic factor.

(Tableons

DISCUSSION
The data presented in this paper indicaLte that there
exists in normal human serum an inactiva .tor of chemotactic factors. This inactivator is heterog4 enous in that,
by a variety of fractionation techniques, the material
appears in two positions. The chemotac tic factor inactivator acts directly and irreversibly otn the chemotactic factor, and it has a broad spectrui mn of activity,
inactivating C567, the chemotactic fragme' nts of C3 and
C5, and the bacterial chemotactic factor derived from
E. coli. It is not possible to completely ex clude the pos-
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sibility that some of the effect of the chemotactic factor
inactivator is cell-directed, but the bulk of the evidence
from these studies strongly suggests otherwise. It should
be noted that normal human serum contains this inactivator, but the amount present is usually too low to
detect in the absence of any fractionation and/or concentration procedures. These would explain why it is
possible to chemotactically activate normal human serum
with agents that trigger the complement system, in spite
of the fact that chemotactic factor inactivator exists in
the serum.
The mechanism by which the inactivator interacts
with the chemotactic factor is not precisely known. The
data in Fig. 4 and Table V do not permit an unambiguous conclusion regarding the mechanism by which the
chemotactic factor inactivator abolishes the chemotactic
activity. It can be clearly stated that this is through a
direct effect on the chemotactic factor rather than by an
effect on leukocytes.
If the mechanism of inactivation of the chemotactic
factors is indeed enzymatic, then the broad spectrum of
action by the chemotactic factor inactivator may imply
a common functional and structural region in each of the
chemotactic factors. There may be an analogy in previous chemotactic studies where it was demonstrated that
deactivation of leukocytes by way of complement chemotactic factors eliminates subsequent chemotactic responto any of the complement-derived or the bacterial (E. coli) chemoattractants (10). This could be
interpreted to indicate a common receptor on the neutrophil for structurally different factors, or it could
also indicate structurally similar chemotactic factors all
acting on the same receptor. In the latter context, the

siveness

TABLE V
Chemotactic Activity in CS Fragment*
Chemotactic activity in ultracentrifugal fractions.
Fraction
tested
(25 jA)

12
13
14
15

fragment
untreated

fragment

Loss of
chemotactic

treated$

activity

110
160
165

20
40
65

82

20

30

0

75
61

pug

* Obtained by isolation of trypsin treated C5. 5
C5 fragment were fractionated in each of two gradients.
$ The chemotactically active C5 fragment from 5 Ag (volume
of 50 ul) was incubated with 10 ul (approximately 25 pug

protein) of inhibitor-rich fraction of serum. After incubation
370C X 20 min, ultracentrifugal separation, shown in
Fig. 2, was performed. Chemotactic activity in various fractions from each of two gradients was then assessed.

at

of a highly purified preparation of the latter. In part,
the difficulty in resolving this question relates to the
unknown chemical relationship between the chemotactic
peptides of C3 and C5 and the homologous anaphylatoxins, C3a and C5a. There is highly suggestive evidence
in favor of the nonidentity of the homologous peptides with anaphylatoxin and chemotactic function. Although treatment of purified C3 and C5 with trypsin
leads to the production of fragments with anaphylatoxin
and chemotactic activity, continued treatment with trypsin results in the disappearance of anaphylatoxin,
whereas there is no demonstrable loss in chemotactic
activity (17, 18). Since there is a fundamental question
regarding structure relationship between the anaphylatoxins and the chemotactic factors, extrapolations between the data from AI and those of the chemotactic
factor inactivator are difficult. Furthermore, it should
be pointed out that while human serum cannot be activated to produce anaphylatoxin (2, 17), there is little
difficulty in activating human serum with an immune
complex so as to generate chemotactic activity (3, 4).
These findings indicate that chemotactic activity which
is generated in human serum by complement activating
substances is resistant to the effects of inactivators
naturally present in serum, either because the chemotactic factors are not susceptible to the inactivators, or
because they are generated in quantities too great to be
handled by the levels of inactivators. Whatever the case
may be, the ability to generate chemotactic activity in
human serum certainly stands in sharp contrast to that
inability to generate anaphylatoxin activity in whole
human serum. It should be stressed that, while some
obvious differences exist between AI and the serum
inhibitor of chemotactic factors, as revealed by fractionation procedures, there is no definitive answer to the
question of identity or nonidentity of the two inactivators. Perhaps the most relevant point in our data
is the demonstration of a naturally occurring chemotactic factor inactivator in human serum. Data will be
presented in a subsequent paper to show the presence
of this inactivator in super-normal amounts in pathologic human sera.
The problem of a better assay for the chemotactic
factor inactivator is obvious. When the inactivator is
sufficiently purified, it should be feasible to develop an
immunochemical assay that would allow detection of the
inactivator in whole serum. Alternatively, when the
structural definitions of the various chemotactic factors
are obtained, it is possible that this information can be
translated into chemical changes in the chemotactic
factors reflecting the action of the chemotactic factor
used in this paper: AI, anaphylatoxin in- inactivator. For the present, however, the functional
assay will remain.

broad activity of the chemotactic factor inactivator
would be readily explicable.
It is not surprising that in human serum there should
exist an inactivator of chemotactic factors, whether
these be products of intrinsic proteins such as complement, or products of extrinsic agents such as bacteria.
In the cases of the kinins and anaphylatoxins, potent inhibitors present in serum inactivate these biologically
active peptides in an irreversible and enzymatic manner
(2, 11). Other inhibitors such as the C-1 inhibitor (12),
a2-macroglobulin (13) and a,-antitrypsin (14) exert a
regulatory function by stoichometric-binding with a
number of enzymes, resulting in their inactivation,
thereby limiting the action of kinin-producing, fibrinolytic, complement and coagulation pathways. ai-antitrypsin also inactivates the neutrophil-derived neutral
protease and elastase (15), providing a control mechanism to prevent undue destruction of tissue proteases
by leukocytic enzymes. It would be anticipated that active substances such as the chemotactic factors would
fall under similar control, otherwise one would predict
uncontrolled mobilization of leukocytes into foci containing chemotactic factors.
A major question arising from these studies concerns
the relationship of the inhibitor of chemotactic factors
and the anaphylatoxin inactivator (AI) 1 described by
Bokisch et al. (2). AI is a pseudoglobin with an electrophoretic mobility of an a-globulin, a molecular weight
of 325,000, and is present in normal human serum. This
inactivator has carboxypeptidase B activity and largely
accounts for the ability of normal human serum to
rapidly destroy the kinins generated by kallikrein and
the anaphylatoxin peptides C3a and C5a. To what extent are AI and the inactivator of chemotactic factor
identical? On the basis of the data presented in this
paper there are some similarities between the two inhibitors. On the other hand, there are several significant
differences. As shown by ultracentrifugal, electrophoretic, and molecular sieving techniques, the chemotactic
factor inhibitor is heterogenous, consisting of two different substances. Bokisch et al. (2) described a single
form of AI in serum, but later work has revealed that
Al may exist in serum as a polymer, raising the possibility that under different conditions AI may have variable physical features (16). Evidence to date indicates
that the chemotactic factor inactivator is not impaired
in the presence of phenanthroline at 10' M. Such results
would suggest that the chemotactic factor inactivator
is not identical with AI (2). The resolution of the basic
question about identity or nonidentity of AI and the
chemotactic factor inactivator must await availability

1Abbreviation

activator.
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